AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd (RQ Bio) for a portfolio of early-stage monoclonal antibodies (mAbs) targeted against SARS-CoV-2, the virus that causes COVID-19. Under the agreement, AstraZeneca has acquired ...
RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio’s existing mAbs against SARS-CoV-2. The Company, ...
LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has signed a licensing agreement with AstraZeneca PLC (AZN). Under the terms of the agreement, RQ Bio has granted AstraZeneca an exclusive ...